Jeff Yass’s Xeris Biopharma Holdings XERS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $2.22M | Buy |
232,184
+92,266
| +66% | +$779K | ﹤0.01% | 6043 |
|
|
2026
Q2 | $1.11M | Sell |
139,918
-146,153
| -51% | -$933K | ﹤0.01% | 7934 |
|
|
2026
Q1 | $1.66M | Buy |
286,071
+168,716
| +144% | +$1.12M | ﹤0.01% | 6604 |
|
|
2025
Q4 | $921K | Buy |
117,355
+35,884
| +44% | +$282K | ﹤0.01% | 7374 |
|
|
2025
Q3 | $663K | Sell |
81,471
-324,731
| -80% | -$2.16M | ﹤0.01% | 8335 |
|
|
2025
Q2 | $1.9M | Sell |
406,202
-231,580
| -36% | -$1.06M | ﹤0.01% | 5904 |
|
|
2025
Q1 | $3.5M | Buy |
637,782
+530,438
| +494% | +$2.14M | ﹤0.01% | 4347 |
|
|
2024
Q4 | $364K | Buy |
107,344
+27,429
| +34% | +$88.2K | ﹤0.01% | 9397 |
|
|
2024
Q3 | $228K | Buy |
79,915
+47,669
| +148% | +$122K | ﹤0.01% | 10189 |
|
|
2024
Q2 | $72.6K | Buy |
32,246
+4,856
| +18% | +$9.8K | ﹤0.01% | 11227 |
|
|
2024
Q1 | $60.5K | Sell |
27,390
-135,839
| -83% | -$351K | ﹤0.01% | 11475 |
|
|
2023
Q4 | $384K | Buy |
163,229
+56,998
| +54% | +$105K | ﹤0.01% | 9287 |
|
|
2023
Q3 | $198K | Sell |
106,231
-17,441
| -14% | -$40K | ﹤0.01% | 10243 |
|
|
2023
Q2 | $324K | Sell |
123,672
-9,721
| -7% | -$24.7K | ﹤0.01% | 9278 |
|
|
2023
Q1 | $217K | Buy |
133,393
+69,824
| +110% | +$87.4K | ﹤0.01% | 10421 |
|
|
2022
Q4 | $84.5K | Sell |
63,569
-32,218
| -34% | -$45.5K | ﹤0.01% | 11090 |
|
|
2022
Q3 | $149K | Buy |
95,787
+32,395
| +51% | +$53.6K | ﹤0.01% | 11246 |
|
|
2022
Q2 | $98K | Sell |
63,392
-359,784
| -85% | -$759K | ﹤0.01% | 11501 |
|
|
2022
Q1 | $1.08M | Sell |
423,176
-411,360
| -49% | -$1M | ﹤0.01% | 6912 |
|
|
2021
Q4 | $2.44M | Buy |
834,536
+225,009
| +37% | +$486K | ﹤0.01% | 5045 |
|
|
2021
Q3 | $1.49M | Buy |
609,527
+528,795
| +655% | +$1.54M | ﹤0.01% | 6499 |
|
|
2021
Q2 | $329K | Buy |
+80,732
| New | +$308K | ﹤0.01% | 10568 |
|
|
2021
Q1 | – | Sell |
-145,255
| Closed | -$783K | – | 12927 |
|
|
2020
Q4 | $715K | Buy |
+145,255
| New | +$727K | ﹤0.01% | 7493 |
|
|
2020
Q3 | – | Sell |
-12,392
| Closed | -$49.5K | – | 11236 |
|
|
2020
Q2 | $33K | Sell |
12,392
-4,126
| -25% | -$14.4K | ﹤0.01% | 9851 |
|
|
2020
Q1 | $32K | Buy |
+16,518
| New | +$71K | ﹤0.01% | 9815 |
|
|
2019
Q4 | – | Sell |
-20,039
| Closed | -$197K | – | 10783 |
|
|
2019
Q3 | $197K | Buy |
20,039
+9,700
| +94% | +$109K | ﹤0.01% | 9107 |
|
|
2019
Q2 | $118K | Buy |
+10,339
| New | +$109K | ﹤0.01% | 9526 |
|
Other funds holding XERS
Jeff Yass's XERS Position: Q3 2026 in Review
Jeff Yass increased its Xeris Biopharma Holdings (XERS) stake by 66% in Q3 2026, buying an estimated $779K and bringing the position to 232,184 shares worth $2.22M. The position accounts for ﹤0.01% of the portfolio, ranked #6043.
Jeff Yass first reported a position in XERS in Q2 2019 and has held it in 27 quarters since. The position peaked at $3.5M in Q1 2025. 249 funds tracked by Wall St. Rank hold XERS as of Q3 2026.
- Jeff Yass held 232,184 shares of Xeris Biopharma Holdings worth $2.22M as of Q3 2026.
- Jeff Yass bought 92,266 Xeris Biopharma Holdings shares in Q3 2026, an estimated $779K.
- Xeris Biopharma Holdings made up ﹤0.01% of Jeff Yass's portfolio in Q3 2026, its #6043 holding.
- Jeff Yass first reported a position in Xeris Biopharma Holdings in Q2 2019 and has held it in 27 quarters since.
- Jeff Yass's Xeris Biopharma Holdings position peaked at $3.5M in Q1 2025.
- 249 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q3 2026.
Based on Susquehanna International Group's 13F filing for Q3 2026, filed 16 Nov 2026.